Skin

LiVDerm Introduces New Agenda and Faculty to Feature in the 2023 South Beach Symposium

Retrieved on: 
Thursday, January 12, 2023
Q&A, Practitioner, Dermatology, Catalog, Student, MS, Learning, Heart, Female, Anatomy, Surgeon, Boxed, Skin, Knowledge, Faculty, JD, Genomics, Chairperson, Patient, Woman, Wound healing, SBS, Doctor of Philosophy, Regenerative medicine, Physician, Health, Medical device, Medicine, MD

Set in the heart of Miami Beach, SBS is an exciting learning experience that goes deeper than the surface of skin, delivering a unique blend of medical and aesthetic dermatology education.

Key Points: 
  • Set in the heart of Miami Beach, SBS is an exciting learning experience that goes deeper than the surface of skin, delivering a unique blend of medical and aesthetic dermatology education.
  • The summit also features Matthew D. Mansh, MD , and new SBS speakers, Frances W. Grimstad, MD, MS , and Ronda S. Farah, MD .
  • Led by world-renowned medical, aesthetic, and pediatric dermatology experts, LiVDerm empowers providers to educate, collaborate, and engage.
  • With a multipronged approach to mastering the myriad of subspecialties within the field, LiVDerm provides innovative and integrated education across the dermatology spectrum.

ViaDerma Engages Intent Sciences to Power Up Digital Marketing & Brand Development

Retrieved on: 
Thursday, January 12, 2023
Social media, Dressing (medical), OTC Markets Group, MRSA, B2B, Impetigo, Psoriasis, Skin, Growth, DTC, Fortune 500, SEO, Dermatitis, Burn, Video game

Their distributed team of digital marketing experts specializes in scaling out personalized digital marketing growth systems that have helped produce over $1 Billion in sales revenue online for dozens of brands to date.

Key Points: 
  • Their distributed team of digital marketing experts specializes in scaling out personalized digital marketing growth systems that have helped produce over $1 Billion in sales revenue online for dozens of brands to date.
  • “We’re very honored and excited to be working with ViaDerma to help grow the brand and business online.
  • The INTENT SCIENCES team will be working closely with ViaDerma management to help grow the B2B & DTC demand side for ViaDerma licensing and lead product Vitastem Ultra.
  • ViaDerma President & CEO, Dr. Chris Otiko said, “We are thrilled to bring INTENT SCIENCES in at this time to help us move forward in this new year.

Emerald Health Pharmaceuticals Receives Safety Review Committee Approval to Proceed to Final Cohorts of EHP-101 Phase 2a Systemic Sclerosis Trial

Retrieved on: 
Wednesday, January 11, 2023
Emerald, Disease, Pharmacokinetics, Safety, FDA, Skin, SRC, Plasma, Patient, Physician, Fibrosis, SAN, Pharming, Systemic scleroderma, Scleroderma, EHP, Pharmaceutical industry

The SRC is comprised of two physicians, one independent and the other the principal investigator in the trial.

Key Points: 
  • The SRC is comprised of two physicians, one independent and the other the principal investigator in the trial.
  • This SSc Phase 2a trial is a double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of EHP-101 in patients with SSc.
  • EHP has completed the first two cohorts, each with nine SSc patients, administering two doses either once daily or twice daily.
  • The Company applied for this amendment to create a pathway to possibly advance directly into a Phase 3 clinical trial of EHP-101 in patients suffering from SSc once the Phase 2a trial is completed, rather than first conducting a Phase 2b before continuing to a Phase 3 trial.

Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company

Retrieved on: 
Tuesday, January 10, 2023
IND, Degenerative disease, T-cell lymphoma, Blood, Plasma, MDM2, Lymphatic system, Sanofi, Entrepreneurship, Mass spectrometry, Cancer, TPD, Therapy, AML, Acute myeloid leukemia, Leukemia, Safety, SAD, Biomarker, FDA, PD, HS, Inflammation, AD, Skin, Toxic leukoencephalopathy, Conference, IV, Patient, Apoptosis, Immunomodulatory imide drug, Cycle, Atopic dermatitis, MYD88, Research, STAT3, MAD, Hidradenitis suppurativa, Human, Investment, Doctor of Philosophy, DLBCL, Follicular lymphoma, Fine chemical, Pharmaceutical industry, Vaccine, IRAK4, Black Majesty, PBMC

WATERTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced its research, development and corporate goals for 2023.

Key Points: 
  • WATERTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced its research, development and corporate goals for 2023.
  • Initial Phase 2 clinical trials of KT-474 will investigate its potential in HS and AD, with the first study initiating in 2023.
  • In December 2022 Kymera announced that Dose Level (DL) 1 had been completed with a total of 4 patients enrolled.
  • Nello Mainolfi, PhD, Co-Founder, President and CEO of Kymera, will provide an overview of the Company’s progress and 2023 goals.

Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, Including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare Diseases

Retrieved on: 
Tuesday, January 10, 2023
MDS, Toxicity, Therapy, Hives, Acute myeloid leukemia, Trial of the century, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmacokinetics, B cell, Environment, Asthma, Skin, Conditional sentence, Lung, Fanconi anemia, Food, Degenerative disease, Patient, Transplant, Clinical trial, SCID, Sickle cell disease, Pharmaceutical industry, Jasper

This portfolio includes a new program on chronic urticaria, along with the Company’s existing programs for lower-risk myelodysplastic syndrome (MDS), sickle cell disease, Fanconi anemia and severe combined immunodeficiency (SCID).

Key Points: 
  • This portfolio includes a new program on chronic urticaria, along with the Company’s existing programs for lower-risk myelodysplastic syndrome (MDS), sickle cell disease, Fanconi anemia and severe combined immunodeficiency (SCID).
  • Based on preclinical and clinical studies showing inhibition of c-Kit signaling, depletion of mast cells in skin and lung and extended pharmacokinetics of subcutaneous dosing, the Company has prioritized rapidly starting a clinical study in severe chronic urticaria.
  • Clinical studies with briquilimab and investigational agents from other companies suggest that targeting c-Kit has strong therapeutic potential for chronic mast cell diseases such as urticaria and allergic asthma.
  • “We believe prioritizing these opportunities provides the best path forward to near-term, clinical milestones for patients and value creation for investors,” added Mr. Martell.

STRATA Skin Sciences Expands into $300 Million Market with Exclusive Distribution Agreement in Mexico

Retrieved on: 
Monday, January 9, 2023
Vitiligo, Acne, STRATA, Skin, Psoriasis, Partnership, Strata Skin Sciences, Marketing, Acquisition, Pharmaceutical industry

“We are excited to have entered into an exclusive sales agreement with MINO Labs,” stated Bob Moccia, Chief Executive Officer of STRATA Skin Sciences.

Key Points: 
  • “We are excited to have entered into an exclusive sales agreement with MINO Labs,” stated Bob Moccia, Chief Executive Officer of STRATA Skin Sciences.
  • “With the addition of Mexico, STRATA has the potential to access a nearly $300 million market for acne, psoriasis, and vitiligo.
  • MINO’s 20 years of experience in the pharmaceutical industry and deep expertise in the Central and Latin American region, will allow STRATA to provide those in Mexico who suffer from skin conditions another treatment option.
  • In particular, there is a high need for acne treatments as 80%1 of the Mexican population is affected by low to severe acne.

Clean Slate Ink Opens Second Location in Austin, TX Featuring the Asclepion PicoStar® and MeDioStar® Lasers backed by Astanza

Retrieved on: 
Monday, January 9, 2023
Slate, Silver, XL, Laser, Skin, Pulse, Hope, Human, Lymphatic system, Ink, Asclepeion, Taste, Hair removal, Orders of magnitude (area), Printed circuit board, Gold

AUSTIN, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Clean Slate Ink , Round Rock’s leading laser provider, has expanded its laser tattoo and hair removal services to South Austin, featuring two new lasers, the Asclepion PicoStar® and MeDioStar®, backed by Astanza.

Key Points: 
  • AUSTIN, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Clean Slate Ink , Round Rock’s leading laser provider, has expanded its laser tattoo and hair removal services to South Austin, featuring two new lasers, the Asclepion PicoStar® and MeDioStar®, backed by Astanza.
  • Since opening its doors in 2018, Clean Slate Ink quickly became a staple name in the greater Austin laser scene.
  • “Clean Slate Ink has grown tremendously over the years thanks to the amazing clients we’ve had the opportunity of serving and the cutting-edge technology we’ve invested in,” said Chris Harris, owner.
  • Customers can choose a Silver, Gold, Rose Gold, or Platinum Package with simple scheduling and no time limitations.

Derm-Biome Pharmaceuticals’ Multi-Target Topical Drug Produces Positive Results in Preclinical Study in Acne

Retrieved on: 
Monday, January 9, 2023
Disease, University of California, San Francisco Fetal Treatment Center, Acne, University, Benzoyl peroxide, School, Quality of life, Safety, MD, Bacteria, The Hospital Research Foundation, Prevalence, Atopic dermatitis, UCSD, University of California, San Diego, Doctor of Philosophy, The Pediatric Infectious Disease Journal, Skin, Pharmaceutical industry, Dietary supplement, Dermatology, Medicine

The psychological impact of acne is substantial, causing profound negative social effects on the quality of life.

Key Points: 
  • The psychological impact of acne is substantial, causing profound negative social effects on the quality of life.
  • There are currently no satisfactory treatments for acne that combine high efficacy and acceptable safety.
  • The global acne treatment market size is forecast to reach as high as $16.9B USD by 2030 (Precedence Research).
  • We feel that it has significant potential to be a first-line treatment for acne and atopic dermatitis, two inflammatory skin diseases with substantial unmet need.”

Trex Expands Transcend® Lineage™ Line With Two New Colors and an Extended 50-year Warranty

Retrieved on: 
Monday, January 9, 2023
Residential Building & Real Estate, Commercial Building & Real Estate, Manufacturing, Construction & Property, Landscape, Architecture, Other Manufacturing, Retail, Home Goods, Other Construction & Property, Chemicals, Plastics, Jasper, New York, Nail, Trex, Trex Company, Inc., Skin, NYSE, Marketing, Transcend, Water, Beauty, Fascia, Engineering, Pedigree, ESG, Forest, TREX, Television, Wood, Cassette tape, Wood-plastic composite, Lumber

Expanding its industry-leading decking portfolio, these new hues boast premium aesthetics, heat-mitigating technology, and superior performance backed by an impressive 50-year warranty.

Key Points: 
  • Expanding its industry-leading decking portfolio, these new hues boast premium aesthetics, heat-mitigating technology, and superior performance backed by an impressive 50-year warranty.
  • In conjunction with the launch of the new Lineage colors, Trex is introducing a 50-year limited warranty for all Trex Transcend and Trex Transcend Lineage decking products.
  • In addition to increasing warranty length for its top-of-the-line Transcend products, Trex also has increased the warranties for its Trex Select® decking from 25 to 35 years.
  • Trex Enhance® products retain their current 25-year warranties, and all Trex decking products continue to be backed by a 10-year Commercial Warranty.

Collagen Supplement Global Market Report 2022: Rising Awareness of Health Benefits Drives Adoption - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Medical Supplies, Health, Tendon, Ortho, R, Osteoporosis, Nail, F&B, Scoliosis, Skin, Joint, Growth, Rheumatoid arthritis, Prevalence, Ligament, Research, Arthritis, Muscle, Hair, Food, Dietary supplement

The global collagen supplement market size reached US$ 2.06 Billion in 2021.

Key Points: 
  • The global collagen supplement market size reached US$ 2.06 Billion in 2021.
  • Besides this, the rising awareness among the masses about the benefits of collagen supplements to prevent collagen deficiency in the body is contributing to the growth of the market.
  • This, along with the growing utilization of collagen supplements in the food and beverage (F&B) industry, is offering a positive market outlook.
  • The publisher provides an analysis of the key trends in each sub-segment of the global collagen supplement market report, along with forecasts at the global, regional and country level from 2022-2027.